An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe

• Published in: Amyotrophic lateral sclerosis and frontotemporal degeneration 2017-10, Vol.18 (sup1), p.88-97
• Main Authors: Takei, Koji, Tsuda, Kikumi, Takahashi, Fumihiro, Hirai, Manabu, Palumbo, Joseph
• Format: Article
• Language: English
• Subjects: Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - diagnosis; Amyotrophic Lateral Sclerosis - drug therapy; Amyotrophic Lateral Sclerosis - epidemiology; Clinical Trials as Topic - methods; Clinical Trials as Topic - standards; Demography - methods; Demography - standards; Disease Progression; edaravone; Europe - epidemiology; Female; guideline; Humans; Japan - epidemiology; Male; Neuroprotective Agents - therapeutic use; Practice Guidelines as Topic - standards; treatment patterns; United States - epidemiology
• ISSN: 2167-8421; 2167-9223
• DOI: 10.1080/21678421.2017.1361445

Background: There is an increasing clinical research focus on neuroprotective agents in amyotrophic lateral sclerosis (ALS). However, it is unclear how generalisable clinical study trial results are between different countries and regions. Objective: To assess similarities and differences in clinical practice and treatment guidelines for ALS, and also to compare the demographics and rate of progression of disease in patients with ALS enrolled in clinical trials in Japan, the US, and Europe. Methods: We performed a review of clinical studies published since 2000 to compare the demographics and characteristics of patients with ALS. Progression of ALS disease was assessed in patients receiving placebo. The changes per month in ALSFRS-R score were calculated and compared between the studies. Results: Overall, diagnostic criteria, recognition of ALS symptoms, comorbidities, use of riluzole, and nutritional, and respiratory support were similar. Regarding demographics and characteristics, there were no clear differences in the incidence of sporadic ALS (range 91-98%), bulbar onset (range 11-41%), and median time from onset to diagnosis (range 9-14 months) among the populations despite the difference in race between regions. However, use of tracheostomy-based invasive respiratory support was higher in Japan (29-38%) than in the US (4%) and Europe (1-31%). Rate of progression of disease was similar between the US and Europe study populations (range -0.89 to -1.60 points/month), and the Japanese study populations (range -1.03 to -1.21 points/month). Conclusion: There is evidence to support the generalisability of data from the Japanese ALS trial experience to the US and Europe populations in early to mid-stage of ALS.